Hypokalaemia · children (2 to < 18 years) in the general population
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hypertension · Adults (general population)
Summary of findings table ‐ LSSS intervention showed no clear difference in hypertension compared with regular salt (low certainty).
1 finding from 1 review
Blood pressure target achievement · Adults (general population)
It is very uncertain whether summary of findings table ‐ LSSS intervention changes blood pressure control compared with regular salt (very low certainty).
1 finding from 1 review
Cardiovascular events · Adults (general population)
It is very uncertain whether summary of findings table ‐ LSSS intervention changes cardiovascular events: various compared with regular salt (very low certainty).
1 finding from 1 review
Cardiovascular events: non‐fatal stroke · Adults (general population)
Summary of findings table ‐ LSSS intervention showed no clear difference in cardiovascular events: non‐fatal stroke compared with regular salt (moderate certainty).
1 finding from 1 review
Cardiovascular events: non‐fatal acute coronary syndrome (events per 100,000 person‐years) · Adults (general population)
Summary of findings table ‐ LSSS intervention probably leads to lower cardiovascular events: non‐fatal acute coronary syndrome (events per… compared with regular salt (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · Adults (general population)
Summary of findings table ‐ LSSS intervention showed no clear difference in cardiovascular mortality (events per 100,000 person‐years) compared with regular salt (moderate certainty).
1 finding from 1 review
Stroke mortality (events per 100,000 person‐years) · Adults (general population)
It is very uncertain whether summary of findings table ‐ LSSS intervention changes stroke mortality (events per 100,000 person‐years) compared with regular salt (very low certainty).
1 finding from 1 review
All‐cause mortality up to 30 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in all‐cause mortality up to 30 days compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).
1 finding from 1 review
All‐cause mortality up to 120 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) changes all‐cause mortality up to 120 days compared with low‐dose dexamethasone (6 mg to 8 mg) (very low certainty).
1 finding from 1 review
Clinical improvement: discharged alive ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in clinical improvement: discharged alive ( compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).
1 finding from 1 review
Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Adverse events: all grades · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Hospital‐acquired infections ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Invasive fungal infection · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Cognitive outcome · preterm infants
3 findings from 1 review
no estimate extracted
25 studies · 3132 participants
Low
no estimate extracted
9 studies · 1524 participants
High
no estimate extracted
6 studies · 1453 participants
Low
Motor outcome in infancy (Bayley, Griffiths Locomotor) · preterm infants
1 finding from 1 review
Motor outcome at preschool age (Griffiths Locomotor, McCarthy, MABC) · preterm infants
1 finding from 1 review
Modified Arhus Index Scale 0‐120 · patients with chronic LBP
1 finding from 1 review